PACS Group, Inc. (PACS)
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-11-05
$50.20-0.12%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-11-05
QuarterlyIQ Insights · PACS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 8.6% |
| Our one-year growth estimate | diamond | 12.6% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 4.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 18 industry peers · Company calendar date is not available
PACS — officer change
Dated 2026-09-21
Chief Legal Officer — John Mitchell: The filing describes the retirement of the Chief Legal Officer with a structured transition agreement and consulting period, indicating an orderly succession rather than a sudden loss of executive leadership.
Why it matters: PACS raised its 2026 revenue range to $5.75–$5.85 billion. Q3 growth above 5% would support that range.
Supportive ifQ3 revenue rises more than 5% year over year, and PACS keeps its $5.75–$5.85 billion 2026 range.
Worry ifQ3 revenue growth is below 3% year over year, or PACS cuts its 2026 range below $5.75 billion.
Why it matters: Q2 adjusted EBITDA was $166.8 million, and full-year guidance rose to $640–$660 million. A strong Q3 would support that higher range.
Supportive ifQ3 adjusted EBITDA is above $160 million, and PACS keeps its $640–$660 million 2026 range.
Worry ifQ3 adjusted EBITDA is below $150 million, or PACS cuts its 2026 range below $640 million.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$126 on $10,000 · ±1.3% | How much price usually moves either way. |
| Bad day | $547 loss on $10,000 · 5.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,789 loss on $10,000 · 27.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.